‘We think the Mag7 are vulnerable’ - Cantor Fitzgerald
Cantor Fitzgerald came out and expressed concerns around the Magnificent Seven group, saying the stocks are “vulnerable.” ...
Cantor Fitzgerald maintains Ascendis Pharma Overweight rating
Cantor Fitzgerald reaffirmed its Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ:ASND) shares, currently trading at $119.49. The firm's analyst highlighted the early adoption of ...
Cantor Fitzgerald maintains Vertex stock Overweight rating
Cantor Fitzgerald reaffirmed its Overweight rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a consistent price target of $480.00. According to InvestingPro data, Vertex, a prominent ...
New York Magazine16h
Trump Cabinet Confirmation Hearings: Schedule & How to Watch
Will the Senate GOP confirm controversial picks like Tulsi Gabbard and RFK Jr.? Here’s the hearings schedule and list of ...
Scotiabank Reaffirms Their Buy Rating on AST SpaceMobile (ASTS)
In a report released today, Andres Coello from Scotiabank maintained a Buy rating on AST SpaceMobile (ASTS – Research Report), with a price ...
Cantor Fitzgerald Forecasts Onto Innovation FY2025 Earnings
Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Onto ...